HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suppressive effects of rare ginsenosides, Rk1 and Rg5, on HMGB1-mediated septic responses.

Abstract
High mobility group box 1 (HMGB1) is considered to be a late mediator of sepsis. The inhibition of HMGB1-mediated severe inflammatory response and restoration of endothelial integrity have emerged as attractive therapeutic strategies for the management of sepsis. Rare ginsenosides, Rk1 (SB1) and Rg5 (SB2), are among the main components of black ginseng and are prepared from ginsenoside Rd by steaming at 120 °C for 3 h. We examined the effects of SB1 and SB2 on HMGB1-mediated septic response and survival rate in a mouse model of sepsis. SB1 and SB2 were administered after challenge with HMGB1. SB1 and SB2 significantly reduced the release of HMGB1 in lipopolysaccharide (LPS)-activated primary human umbilical vein endothelial cells (HUVECS) via the SIRT1-mediated deacetylation of HMGB1. Moreover, SB1 and SB2 suppressed the production of TNF-α and IL-6 and the activation of NF-κB and ERK 1/2 by HMGB1. SB1 and SB2 also inhibited HMGB1-mediated hyperpermeability and leukocyte migration in mice. In addition, treatment with SB1 and SB2 reduced the cecal ligation and puncture-induced release of HMGB1, sepsis-related mortality, and tissue injury in vivo. Our results indicate that SB1 and SB2 might be useful in the treatment of sepsis by targeting HMGB1.
AuthorsJi-Eun Kim, Wonhwa Lee, Sumin Yang, Soo-Hyun Cho, Moon-Chang Baek, Gyu-Yong Song, Jong-Sup Bae
JournalFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association (Food Chem Toxicol) Vol. 124 Pg. 45-53 (Feb 2019) ISSN: 1873-6351 [Electronic] England
PMID30496780 (Publication Type: Journal Article)
CopyrightCopyright © 2018 Elsevier Ltd. All rights reserved.
Chemical References
  • Anti-Inflammatory Agents
  • Ginsenosides
  • HMGB1 Protein
  • HMGB1 protein, human
  • ginsenoside Rg5
  • ginsenoside Rk1
  • SIRT1 protein, human
  • Sirtuin 1
Topics
  • Animals
  • Anti-Inflammatory Agents (therapeutic use)
  • Cell Movement (drug effects)
  • Ginsenosides (therapeutic use)
  • HMGB1 Protein (metabolism)
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Lung Injury (drug therapy)
  • Male
  • Mice, Inbred C57BL
  • Neutrophils (drug effects)
  • Sepsis (drug therapy)
  • Sirtuin 1 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: